Why Perfect B Is Evaluating AOD 9604: Our Clinical Perspective We began our internal evaluation of AOD 9604 in response to a consistent pattern we were seeing with patients in our South Florida practice: people who had experienced meaningful fat loss on GLP-1 medications, then plateaued or discontinued due to side effects, and were looking for a next option
That said, most users cycle it simply because fat loss goals are achieved within 3-4 months, or they want to assess baseline after treatment
The canonical structure has a quinolinium core with strategic substitutions that give it unique electronic and steric properties
They should remain separated from the main dosing protocol because the FDA review specifically flagged the absence of published human exposure data for subcutaneous, transdermal, and intranasal routes
By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis via the salvage pathway, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis, fat oxidation, and metabolic flexibility [3]